Want to see ZBIO full AI Analyst Report?
Top Page
Zenas BioPharma, Inc.
(NASDAQ:ZBIO)
Select Model
Select Model
Rating:58Neutral
Price Target:
$33.00
▲(8.59% Upside)
Action:Reiterated
Date:07/02/26
The score is held back primarily by weak financial performance (heavy losses, significant cash burn, and rising debt), partially offset by strong technical momentum and positive corporate developments (extended cash runway and favorable Phase 3 data). Valuation remains unattractive/unclear due to negative earnings and no dividend support.
Positive Factors
Extended cash runway
A large cash balance and recent financings materially extend runway into 2029, providing durable funding for late‑stage programs. This reduces near‑term financing pressure, lets the company complete pivotal trials and regulatory filings, and de‑risks near‑term execution needs.
Negative Factors
Large cash burn
Sustained operating cash outflows (~$210M TTM) mean the business consumes significant capital to fund R&D and operations. Over months, continued high burn increases dilution and refinancing risk, constraining strategic choices and making long‑term independence contingent on successful product milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway
A large cash balance and recent financings materially extend runway into 2029, providing durable funding for late‑stage programs. This reduces near‑term financing pressure, lets the company complete pivotal trials and regulatory filings, and de‑risks near‑term execution needs.
Read all positive factors
Zenas BioPharma, Inc. (ZBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.98B
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth-100.00%
EPS Growth-128.73%
CountryUS
Employees167
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-9.10
Shares Outstanding63,133,377
10 Day Avg. Volume846,352
30 Day Avg. Volume1,025,017
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.56
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$41.40Price Target Upside36.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.81
Revenue Forecast (FY)$30.22M
Zenas BioPharma, Inc. Business Overview & Revenue Model
Company Description
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctiv...
How the Company Makes Money
null...
Zenas BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 10.00M | 5.00M | 50.00M | 0.00 |
| Gross Profit | -103.75M | 10.00M | -134.14M | 50.00M | -61.69M |
| EBITDA | -408.44M | -370.43M | -156.42M | -27.03M | -75.12M |
| Net Income | -425.15M | -377.74M | -156.99M | -37.12M | -119.28M |
Balance Sheet | |||||
| Total Assets | 747.68M | 383.64M | 369.97M | 68.18M | 74.58M |
| Cash, Cash Equivalents and Short-Term Investments | 717.21M | 343.19M | 350.77M | 56.86M | 67.21M |
| Total Debt | 351.73M | 79.96M | 1.00M | 21.11M | 1.53M |
| Total Liabilities | 411.85M | 141.50M | 57.51M | 293.90M | 266.87M |
| Stockholders Equity | 335.83M | 242.14M | 312.46M | -225.72M | -192.29M |
Cash Flow | |||||
| Free Cash Flow | -210.48M | -172.35M | -119.81M | -30.55M | -67.85M |
| Operating Cash Flow | -210.48M | -172.33M | -119.67M | -30.53M | -65.65M |
| Investing Cash Flow | -134.00M | -251.89M | -30.55M | -17.00K | -2.20M |
| Financing Cash Flow | 648.66M | 215.28M | 412.96M | 20.12M | 59.39M |
Zenas BioPharma, Inc. Technical Analysis
Positive
30.39
Price Trends
25.14
Positive
22.72
Positive
25.86
Positive
Market Momentum
1.78
Positive
62.50
Neutral
51.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZBIO, the sentiment is Positive. The current price of 30.39 is below the 20-day moving average (MA) of 30.75, above the 50-day MA of 25.14, and above the 200-day MA of 25.86, indicating a bullish trend. The MACD of 1.78 indicates Positive momentum. The RSI at 62.50 is Neutral, neither overbought nor oversold. The STOCH value of 51.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZBIO.
Zenas BioPharma, Inc. Risk Analysis
Zenas BioPharma, Inc. disclosed 86 risk factors in its most recent earnings report. Zenas BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zenas BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $857.31M | 5.21 | 129.32% | ― | 2889.93% | ― | |
59 Neutral | $1.86B | -13.91 | 121.52% | ― | 52.92% | 13.32% | |
58 Neutral | $1.98B | -3.45 | -167.71% | ― | -100.00% | -128.73% | |
56 Neutral | $454.50M | -5.76 | -58.82% | ― | ― | 29.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $707.88M | -6.84 | 25.70% | ― | 110.16% | 73.04% | |
41 Neutral | $469.79M | -2.65 | -106.22% | ― | -9.42% | -67.60% |
* Healthcare Sector Average
ZBIO
Zenas BioPharma, Inc.
32.17
17.54
119.89%
ABUS
Arbutus Biopharma
4.54
1.14
33.53%
RZLT
Rezolute
4.70
-1.11
-19.10%
URGN
Urogen Pharma
45.60
27.86
156.97%
PHAT
Phathom Pharmaceuticals
8.39
-1.35
-13.86%
VALN
Valneva
5.18
-3.93
-43.14%
Zenas BioPharma, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Zenas BioPharma Highlights Strong Q1 Progress and Financing
Positive
May 13, 2026
On May 11, 2026, Zenas BioPharma stockholders approved two Class II directors for new three-year terms, accepted the resignation of director Tomas Kiselak, and reduced the board size by one, while also ratifying Ernst Young as the auditor for the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.